In breast cancer, small molecules such as pristane and its derivatives target the malonyl/acetyltransferase domain of fatty acid synthase (FASN), disrupting fatty acid‐mediated MHC‐II silencing and thereby promoting CD4+ T cell infiltration.115. The gene discussed is FASN; the disease is breast carcinoma.